Literature DB >> 8565041

Drug utilization review of concomitant use of specific serotonin reuptake inhibitors or clomipramine with antianxiety/sleep medications.

K Rascati1.   

Abstract

Side effects of some antidepressants include anxiety and insomnia. A retrospective drug utilization review was conducted to determine the amount of concurrent use of an antidepressant with medication that may counteract these side effects. Texas Medicaid claims data for 1993 included more than 30,000 patients receiving a specific serotonin reuptake inhibitor (SSRI) or clomipramine. A total of 35.0% of these patients were also taking a medication that could be used to relieve anxiety or induce sleep, and 15.2% of the total were receiving once-daily dosing of the latter type of medication. Concomitant use of SSRIs or clomipramine with trazodone occurred in 7.7% of the patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8565041     DOI: 10.1016/0149-2918(95)80055-7

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  10 in total

1.  Clinical relevance of disturbances of sleep and vigilance in major depressive disorder: a review.

Authors:  Michael E Thase; Harald Murck; Anke Post
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

2.  Risk factors for non-adherence to antidepressant treatment in patients with mood disorders.

Authors:  Carlos De las Cuevas; Wenceslao Peñate; Emilio J Sanz
Journal:  Eur J Clin Pharmacol       Date:  2013-09-08       Impact factor: 2.953

Review 3.  [Sleep disorders in depression. Suggestions for a therapeutic approach].

Authors:  C Zimmermann; H Pfeiffer
Journal:  Nervenarzt       Date:  2007-01       Impact factor: 1.214

Review 4.  Fluoxetine. A pharmacoeconomic review of its use in depression.

Authors:  M I Wilde; P Benfield
Journal:  Pharmacoeconomics       Date:  1998-05       Impact factor: 4.981

Review 5.  Circadian rhythm disturbances in depression.

Authors:  Anne Germain; David J Kupfer
Journal:  Hum Psychopharmacol       Date:  2008-10       Impact factor: 1.672

Review 6.  Clinically important drug interactions with zopiclone, zolpidem and zaleplon.

Authors:  Leah M Hesse; Lisa L von Moltke; David J Greenblatt
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

7.  Agomelatine treatment corrects impaired sleep-wake cycle and sleep architecture and increases MT1 receptor as well as BDNF expression in the hippocampus during the subjective light phase of rats exposed to chronic constant light.

Authors:  Jana Tchekalarova; Lidia Kortenska; Natasha Ivanova; Milena Atanasova; Pencho Marinov
Journal:  Psychopharmacology (Berl)       Date:  2019-11-13       Impact factor: 4.530

8.  Analysis of treatment patterns and persistence on branded and generic medications in major depressive disorder using retrospective claims data.

Authors:  Caitlyn T Solem; Ahmed Shelbaya; Yin Wan; Chinmay G Deshpande; Jose Alvir; Elizabeth Pappadopulos
Journal:  Neuropsychiatr Dis Treat       Date:  2016-10-25       Impact factor: 2.570

9.  Correlates of Psychotropic Polypharmacy in outpatient psychiatric clinics of two military tertiary hospitals in Saudi Arabia.

Authors:  Fares F Alharbi; Samar F Alharbi; Saleh Bin Salih; Khaled Al-Surimi
Journal:  J Family Community Med       Date:  2019 Sep-Dec

10.  Polypharmacy in psychiatric practice in the Canary Islands.

Authors:  Carlos De las Cuevas; Emilio J Sanz
Journal:  BMC Psychiatry       Date:  2004-07-05       Impact factor: 3.630

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.